StoryEditor ExternalStoryEditor Internal
ANTIVIRUSNI PREPARAT

Stigli prvi rezultati istraživanja Merckova oralnog lijeka protiv covida, rezultati su odlični

Lijek je bitno smanjio virusno opterećenje kod pacijenata nakon pet dana liječenja, navodi tvrtka
Piše:
Hina
Objavljeno: 6. ožujka 2021. 22:22
(FILES)This July 8, 2002 photo shows a view of several buildings at pharmaceutical giant Merck and Company in Lansdale, Pennsylvania. - US President Joe Biden plans to announce an arrangement for pharma giant Merck to produce Johnson & Johnson's single-dose Covid-19 vaccine to boost supply, a senior Biden administration told AFP on March 2, 2021. The official confirmed a Washington Post report on the unusual agreement, which is designed to significantly boost vaccine supply as the Biden administration seeks to tame a coronavirus outbreak that has claimed more than 500,000 American lives. (Photo by TOM MIHALEK/AFP)
Premium icon
(FILES)This July 8, 2002 photo shows a view of several buildings at pharmaceutical giant Merck and Company in Lansdale, Pennsylvania. - US President Joe Biden plans to announce an arrangement for pharma giant Merck to produce Johnson & Johnson's single-dose Covid-19 vaccine to boost supply, a senior Biden administration told AFP on March 2, 2021. The official confirmed a Washington Post report on the unusual agreement, which is designed to significantly boost vaccine supply as the Biden administration seeks to tame a coronavirus outbreak that has claimed more than 500,000 American lives. (Photo by TOM MIHALEK/AFP)
 Tom Mihalek
Lijek je bitno smanjio virusno opterećenje kod pacijenata nakon pet dana liječenja, navodi tvrtka

Farmaceutski div Merck i američki laboratorij objavili su u subotu napredak u ispitivanju oralnog lijeka protiv covida-19, antivirusnog preparata koji pozitivno utječe na smanjenje virusnog opterećenja.

"Pošto postoji potreba antivirusnog liječenja SARS-CoV-2, ohrabruju nas ovi preliminarni rezultati", navodi u priopćenju Wendy Painter, dužnosnica u Ridgeback Biotherapeutics.

Merck je krajem siječnja prekinuo rad na dva potencijalna cjepiva protiv covida-19, ali nastavlja istraživanja dva lijeka protiv te bolesti, uključujući molnupiravir, razvijen s američkim tvrtkom Ridgeback Bio.

Lijek je bitno smanjio virusno opterećenje kod pacijenata nakon pet dana liječenja, navela je tvrtka u subotu na sastanku sa stručnjacima za zarazne bolesti.

Druga faza testiranja je provedena n...

Vezane vijesti
#Merck #lijek protiv covida #koronavirus
Želite li dopuniti temu ili prijaviti pogrešku u tekstu?
06. prosinac 2025 15:40